Predicting the outcome of hepatitis C virus treatment

Millions of people throughout the world are infected with hepatitis C virus (HCV), which can lead to cirrhosis of the liver and cancer. Directly acting antiviral agents inhibit viral proteins and have been used to successfully treat HCV. Unfortunately, antiviral therapy fails in some patients, resulting in a relapse of HCV.

A study published in the Journal of Clinical Investigation identifies a marker that can identify patients likely to have an HCV relapse after . Shyamasundaran Kottilil and colleagues at the NIH evaluated the immune response of HCV-infected individuals treated with . Treated patients that had increased expression of type I interferon were more likely to remain HCV-free. Patients unable to maintain a type I interferon response were more likely to have an HCV relapse.

This study provides a potential marker to identify patients prone to HCV relapse. Moreover, these results suggest that type I interferon treatment in at-risk patients merits future study.

More information: Endogenous intrahepatic IFNs and association with IFN-free HCV treatment outcome, J Clin Invest. DOI: 10.1172/JCI75938

add to favorites email to friend print save as pdf

Related Stories

Recommended for you

Ebola: Why virus kills some, other people survive

16 minutes ago

People who shared an apartment with the country's first Ebola patient are emerging from quarantine healthy. And while Thomas Eric Duncan died and two U.S. nurses were infected caring for him, there are successes, ...

Sleep duration affects risk for ulcerative colitis

2 hours ago

If you are not getting the recommended seven-to-eight hours of sleep each night, you may be at increased risk of developing ulcerative colitis, according to a new study1 in Clinical Gastroenterology and Hepatolog ...

User comments